pH-Induced Disaggregation of Beta-Sheet Protein Aggregates
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for diagnosing neurodegenerative diseases associated with β-sheet aggregate forms of proteins are cumbersome, expensive, and lack sensitivity, particularly in measuring the content of β-sheet non-aggregate forms of proteins, which are essential for understanding aggregation modulation by compounds.
Innovation Solution
An in vitro method involving pH adjustment to range from 9.7 to 13.2 to disaggregate β-sheet aggregate forms of proteins, followed by pH adjustment to 6-9 for measuring the β-sheet non-aggregate form content using immunological methods, allowing for precise detection and comparison of protein aggregation levels.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If pH is adjusted to 9.7-13.2 to disaggregate β-sheet aggregates, then measurement precision of non-aggregate forms is improved, but device complexity increases due to pH control requirements
Solution Approach 1:
The patent applies parameter changes by adjusting the pH value to a specific range (9.7-13.2) to induce disaggregation of β-sheet aggregates. This chemical parameter modification transforms the aggregate state into a measurable non-aggregate state, enabling accurate quantification of protein aggregation levels through immunological detection methods.
2Measurement precision
If immunological methods are used to measure PNAFβ content, then measurement precision is improved, but ease of operation deteriorates due to complex immunological procedures
Solution Approach 1:
The patent applies preliminary action by first adjusting the pH to disaggregate the β-sheet aggregates before performing immunological measurement. This pre-treatment step converts the aggregates into a form that can be accurately measured by immunological methods, simplifying the overall measurement process while maintaining high precision.
3Measurement precision
If disaggregation is performed to measure PNAFβ, then measurement precision of aggregation levels is improved, but loss of substance occurs during pH adjustment and disaggregation
Solution Approach 1:
The patent minimizes substance loss by optimizing the pH adjustment parameters within the specific range of 9.7-13.2. This controlled parameter change achieves effective disaggregation while minimizing protein degradation or precipitation that could lead to substance loss, ensuring accurate measurement of the original protein content.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method provides a simple, fast, and reliable means to detect β-sheet aggregate forms of proteins, overcoming the limitations of existing techniques by enabling accurate measurement of protein aggregation levels and monitoring therapeutic or pharmacological efficacy.
Implementation Method 1
a2) adjusting the pH to a pH ranging from 9.7 to 13.2 to disaggregate all or one portion of the PAFβ in order to obtain a β-sheet non-aggregate form of the protein forming β-sheet aggregates (PNAFβ)
Data Source
AI summary
The invention relates to an in-vitro method for detecting in a sample a β-sheet aggregate form of a protein forming β-sheet aggregates (PAPβ), comprising a step of adjusting the pH of a sample likely to contain PAPβ at a pH ranging from 9.7 to 13.2 in order to separate out all or one portion of the PAPβ in order to obtain a β-sheet non-aggregate form of the protein forming β-sheet aggregates (PNAPβ) and measuring the PNAPβ content with an appropriate immunological method at a pH ranging from 6 to 9.